Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

摘要: Context: Data regarding gender-specific efficacy of GH on critical endpoints are lacking. There no randomized, placebo-controlled studies physiological therapy solely in women. Objective: Our objective was to determine the effects replacement cardiovascular risk markers and body composition women with deficiency (GHD). Design: This a 6-month, placebo-controlled, double-blind study. Setting: The study conducted at General Clinical Research Center. Study Participants: 43 GHD due hypopituitarism were included Intervention: participants randomized receive (goal mid-normal serum IGF-1) or placebo. Main Outcome Measures: Cardiovascular markers, including high-sensitivity C-reactive protein, tissue plasminogen activator, composition, visceral adipose by cross-sectional computed tomography, measured. Results: Mean daily dose 0.67 mg. mean IGF-1 sd score increas...